[go: up one dir, main page]

DK0966285T3 - Anvendelse af (+)mefloquin til behandling af malaria - Google Patents

Anvendelse af (+)mefloquin til behandling af malaria

Info

Publication number
DK0966285T3
DK0966285T3 DK98910836T DK98910836T DK0966285T3 DK 0966285 T3 DK0966285 T3 DK 0966285T3 DK 98910836 T DK98910836 T DK 98910836T DK 98910836 T DK98910836 T DK 98910836T DK 0966285 T3 DK0966285 T3 DK 0966285T3
Authority
DK
Denmark
Prior art keywords
quinolinemethanol
piperidinyl
trifluoromethyl
alpha
bis
Prior art date
Application number
DK98910836T
Other languages
Danish (da)
English (en)
Inventor
Allan Fletcher
Robin Shepherd
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704809.4A external-priority patent/GB9704809D0/en
Priority claimed from GBGB9722232.7A external-priority patent/GB9722232D0/en
Priority claimed from GBGB9724263.0A external-priority patent/GB9724263D0/en
Priority claimed from GBGB9724712.6A external-priority patent/GB9724712D0/en
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of DK0966285T3 publication Critical patent/DK0966285T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK98910836T 1997-03-07 1998-03-06 Anvendelse af (+)mefloquin til behandling af malaria DK0966285T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9704809.4A GB9704809D0 (en) 1997-03-07 1997-03-07 Chemical compounds
GBGB9722232.7A GB9722232D0 (en) 1997-10-21 1997-10-21 Chemical compounds
GBGB9724263.0A GB9724263D0 (en) 1997-11-17 1997-11-17 Chemical compounds
GBGB9724712.6A GB9724712D0 (en) 1997-11-21 1997-11-21 Chemical compounds
PCT/GB1998/000675 WO1998039003A1 (fr) 1997-03-07 1998-03-06 Utilisation de (+)mefloquine dans le traitement du paludisme

Publications (1)

Publication Number Publication Date
DK0966285T3 true DK0966285T3 (da) 2002-10-28

Family

ID=27451612

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98910836T DK0966285T3 (da) 1997-03-07 1998-03-06 Anvendelse af (+)mefloquin til behandling af malaria

Country Status (10)

Country Link
US (1) US6664397B1 (fr)
EP (1) EP0966285B1 (fr)
JP (1) JP4380800B2 (fr)
AT (1) ATE225177T1 (fr)
AU (1) AU730818B2 (fr)
DE (1) DE69808440T2 (fr)
DK (1) DK0966285T3 (fr)
ES (1) ES2185153T3 (fr)
PT (1) PT966285E (fr)
WO (1) WO1998039003A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1251499A (en) * 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
GB0021776D0 (en) 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
US20070032480A1 (en) * 2005-06-14 2007-02-08 The Johns Hopkins University Treatment of ischemia-induced arrhythmias
AU2007217892A1 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of Parkinson's Disease
WO2009131657A1 (fr) * 2008-04-21 2009-10-29 Duke University Fonctionnalisation en alpha et double fonctionnalisation en alpha, alpha asymétriques d'aldéhydes et de cétones
WO2010110747A1 (fr) * 2009-03-24 2010-09-30 National University Of Singapore Utilisation de dérivés de l'artémisinine dans le traitement de l'asthme et de la broncho-pneumopathie obstructive chronique (bpco)
US8716265B2 (en) 2010-11-18 2014-05-06 Jenrin Discovery, Inc. 4-quinolinemethanols as anti-malarial agents
EP2487157A1 (fr) 2011-02-11 2012-08-15 Université de Picardie Jules Verne Procédé de synthèse énantiosélectif de dérivés de 4-aminoalcoholquinoline et son utilisation
BR112015002697A8 (pt) * 2012-08-09 2018-01-16 Can Fite Biopharma Ltd uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo
CN103304538B (zh) * 2013-06-21 2014-12-24 中国人民解放军第四军医大学 右旋甲氟喹的合成
CN107149601B (zh) * 2017-05-25 2020-04-17 中国中医科学院中药研究所 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用
US11220482B2 (en) 2017-11-03 2022-01-11 Universite Amiens Picardie Jules Verne Aminopyridinemethanol compounds and their use
CN110507646A (zh) * 2019-09-12 2019-11-29 广州中医药大学(广州中医药研究院) 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2940443A1 (de) 1979-10-05 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system

Also Published As

Publication number Publication date
EP0966285B1 (fr) 2002-10-02
PT966285E (pt) 2002-12-31
ATE225177T1 (de) 2002-10-15
HK1024631A1 (en) 2000-10-20
AU6506898A (en) 1998-09-22
EP0966285A1 (fr) 1999-12-29
AU730818B2 (en) 2001-03-15
DE69808440T2 (de) 2003-07-10
WO1998039003A1 (fr) 1998-09-11
JP2001526637A (ja) 2001-12-18
US6664397B1 (en) 2003-12-16
JP4380800B2 (ja) 2009-12-09
DE69808440D1 (de) 2002-11-07
ES2185153T3 (es) 2003-04-16

Similar Documents

Publication Publication Date Title
DK0966285T3 (da) Anvendelse af (+)mefloquin til behandling af malaria
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
DK0998287T3 (da) Anvendelse af levobupivacain
WO2000071108A3 (fr) Procedes de traitement de l'asthme a l'aide de s-oxybutynine
DK0966277T3 (da) Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
GEP20063754B (en) Quinoline Derivatives and Use Thereof as Antitumor Agents
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
DK1224161T3 (da) Nitroxyderivater af (R)- og (S)-carnitin
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
PT900082E (pt) Utilizacao de piridilpiperazina e pirimidilpiperazina para o fabrico de um medicamento para o tratamento de perturbacoes de toxicomania
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
ATE334982T1 (de) 7-chlor-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-
CA2387394A1 (fr) Utilisation de derives de 1-aminoindan pour le traitement de la manie liee a la psychose maniacodepressive
EE200100193A (et) 3-(1H-imidasool-4-ülmetüül)-indaan-5-ol'i kasutamine intraspinaalselt, teekasiseselt või epiduraalselt manustatava ravimi tootmises
TH42959A (th) สารประกอบเคมี
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors